Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2207
First IPO Date
July 17, 1998
| Name | Title | Pay | Year Born |
| Anne-Kathrin Stoller | Chief Executive Officer | 0 | 1974 |
| Hans van Hees | Chief Operations Officer | 0 | 1969 |
| Gunther Loidl | Chief Technology Officer | 0 | 1970 |
| Achim Pluckebaum | Chief Information Officer | 0 | N/A |
| Daniel Grotzky | Head of Group Communications | 0 | N/A |
| Barbora Blaha | Head of Investor Relations | 0 | N/A |
| Torsten Wohr | Chief Commercial Officer | 0 | 1968 |
| Alain Schaffter | Chief Financial Officer | 0 | 1977 |
| Michael Suter | Vice President of Global Accounting | 0 | N/A |
| Viviane Minden | Chief Human Resources Officer | 0 | N/A |
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.